These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 14764779)

  • 1. Factors influencing mortality in acromegaly.
    Holdaway IM; Rajasoorya RC; Gamble GD
    J Clin Endocrinol Metab; 2004 Feb; 89(2):667-74. PubMed ID: 14764779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O; Beauregard C; Hardy J
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nationwide survey of mortality in acromegaly.
    Kauppinen-Mäkelin R; Sane T; Reunanen A; Välimäki MJ; Niskanen L; Markkanen H; Löyttyniemi E; Ebeling T; Jaatinen P; Laine H; Nuutila P; Salmela P; Salmi J; Stenman UH; Viikari J; Voutilainen E
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4081-6. PubMed ID: 15886256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
    Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess mortality in acromegaly.
    Holdaway IM
    Horm Res; 2007; 68 Suppl 5():166-72. PubMed ID: 18174739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
    Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.
    Jenkins PJ; Bates P; Carson MN; Stewart PM; Wass JA
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1239-45. PubMed ID: 16403824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.
    Barrande G; Pittino-Lungo M; Coste J; Ponvert D; Bertagna X; Luton JP; Bertherat J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3779-85. PubMed ID: 11061538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography.
    Cannavo S; Almoto B; Cavalli G; Squadrito S; Romanello G; Vigo MT; Fiumara F; Benvenga S; Trimarchi F
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3766-72. PubMed ID: 16835284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.